Abstract
Receptor tyrosine kinase inhibitors and monoclonal antibodies are popular EGF (Epidermal growth factor) receptor inhibitors, which hold evolving role in current therapeutic practice. Monoclonal antibodies, generated from a single clone of plasma cells, remain the focus of this review. Considering the fact that monoclonal antibodies based immunotherapy provides a highly efficacious and specific approach for the treatment of several diseases, we present an overview which focuses on methods and technologies used for generation of monoclonal antibodies, followed by their production on large scale. Following production methods, we highlight the basic mode of action of this inimitable class of drugs and their applications in therapeutic practice. We firmly believe that promotion of large scale production of antibody drugs, targeted at specific antigens can provide betterment in therapeutic practices across Pakistan.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
